Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down After Earnings Miss

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) shares gapped down before the market opened on Wednesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $12.02, but opened at $10.90. Day One Biopharmaceuticals shares last traded at $11.0480, with a volume of 798,541 shares.

The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.04). The business had revenue of $53.72 million during the quarter, compared to analysts’ expectations of $49.81 million. Day One Biopharmaceuticals had a negative net margin of 113.53% and a negative return on equity of 32.05%.

Day One Biopharmaceuticals News Roundup

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Record revenue and revenue beat: Q4 product revenues and full‑year receipts accelerated (Q4 net product revenues reported at $52.8M; FY net product revenues $155.4M) and overall Q4 revenue of $53.72M topped analyst estimates. This top‑line strength is the main positive catalyst. Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
• Positive Sentiment: Reaffirmed and growth‑oriented 2026 guidance: management reiterated 2026 U.S. net product revenue guidance of $225–$250M and highlighted the Mersana acquisition (adds Emi‑Le into early clinical development), supporting a growth narrative beyond current OJEMDA™ sales. Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
• Neutral Sentiment: Investor materials and management commentary available: the earnings slide deck, press release and full earnings call/transcript were posted for deeper diligence — useful for assessing product adoption, gross margin trajectory and commercialization expenses but not immediate market drivers. View Press Release / Slide Deck
• Neutral Sentiment: Transcript coverage: multiple transcripts (Seeking Alpha, InsiderMonkey) provide Q&A details on commercial rollout, supply and competition; these are helpful for modeling but require parsing for any near‑term changes to guidance assumptions. Day One Biopharmaceuticals, Inc. (DAWN) Q4 2025 Earnings Call Transcript
• Negative Sentiment: EPS miss and continued losses: reported EPS was −$0.21, missing consensus (−$0.17); the company still shows negative net margins and ROE, which keeps profitability timelines uncertain and could constrain valuation multiples until quarters of sustained margin improvement arrive. Day One Biopharmaceuticals Q4 2025 Earnings Highlights

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on DAWN. TD Cowen started coverage on shares of Day One Biopharmaceuticals in a report on Tuesday, January 13th. They set a “buy” rating and a $34.00 price objective for the company. HC Wainwright dropped their target price on shares of Day One Biopharmaceuticals from $25.00 to $22.00 and set a “buy” rating for the company in a research report on Wednesday. Zacks Research raised shares of Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 26th. Needham & Company LLC decreased their price target on shares of Day One Biopharmaceuticals from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $26.14.

Insider Activity at Day One Biopharmaceuticals

In other news, CFO Charles N. York II sold 6,065 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $70,354.00. Following the sale, the chief financial officer directly owned 312,025 shares in the company, valued at $3,619,490. The trade was a 1.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Jeremy Bender sold 15,459 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $179,324.40. Following the completion of the transaction, the chief executive officer directly owned 204,603 shares of the company’s stock, valued at approximately $2,373,394.80. The trade was a 7.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 36,461 shares of company stock valued at $422,948 over the last quarter. 6.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Institutional investors have recently modified their holdings of the stock. Royal Bank of Canada increased its position in shares of Day One Biopharmaceuticals by 40.4% during the 1st quarter. Royal Bank of Canada now owns 185,733 shares of the company’s stock valued at $1,474,000 after purchasing an additional 53,459 shares during the last quarter. AQR Capital Management LLC boosted its stake in Day One Biopharmaceuticals by 601.4% during the first quarter. AQR Capital Management LLC now owns 618,627 shares of the company’s stock worth $4,906,000 after buying an additional 530,429 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Day One Biopharmaceuticals by 6.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,992 shares of the company’s stock worth $302,000 after buying an additional 2,149 shares during the period. Millennium Management LLC increased its position in Day One Biopharmaceuticals by 587.2% during the first quarter. Millennium Management LLC now owns 1,320,095 shares of the company’s stock valued at $10,468,000 after acquiring an additional 1,127,995 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of Day One Biopharmaceuticals by 232.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,569,918 shares of the company’s stock valued at $12,449,000 after acquiring an additional 1,097,679 shares during the period. 87.95% of the stock is owned by institutional investors.

Day One Biopharmaceuticals Stock Down 7.2%

The company’s 50 day moving average price is $10.63 and its two-hundred day moving average price is $8.74. The firm has a market cap of $1.15 billion, a PE ratio of -7.29 and a beta of -1.26.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.